An ANXA11 P93S variant dysregulates TDP-43 and causes corticobasal syndrome

Allison Snyder, Veronica H. Ryan, James Hawrot, Sydney Lawton, Daniel M. Ramos, Yue Qi, Kory Johnson, Xylena Reed, Nicholas L. Johnson, Aaron W. Kollasch, Megan F. Duffy, Lawren VandeVrede, J. Nicholas Cochran, Bruce L. Miller, Camilo Toro, Bibiana Bielekova, Jennifer S. Yokoyama, Debora S. Marks, Justin Kwan, Mark Cookson, Michael E. WardResearch Square 2023 · DOI

Introduction

The rapid expansion of genetic testing has introduced a significant clinical hurdle: the identification of "variants of uncertain significance" (VUS). While computational models attempt to predict pathogenicity based on evolutionary conservation, they often struggle with proteins containing intrinsically disordered regions. This study addresses a novel VUS (P93S) in the ANXA11 gene, identified in a family presenting with corticobasal syndrome (CBS). By employing a multi-modal biological validation pipeline using human induced pluripotent stem cells (iPSCs), researchers have confirmed the pathogenicity of this variant, expanding the known clinical spectrum of ANXA11 mutations and revealing a complex interplay between neuronal transport and microglial immune dysregulation.

Methods

To investigate the P93S variant, the researchers utilized a comprehensive suite of clinical and molecular tools. They first performed clinical profiling of the affected kindred using MRI and cerebrospinal fluid (CSF) analysis. To validate the variant's functional impact, they engineered human iPSCs to differentiate into cortical-like neurons and microglia. These cells were then modified via lentiviral overexpression to express either wildtype or P93S mutant ANXA11.

Functional assays included live-cell imaging to monitor the colocalization of ANXA11 with lysosomes, and RNAscope to quantify RNA delivery to distal neurites. To assess the downstream impact on RNA metabolism, the team used immunocytochemistry to track TDP-43 localization and developed a novel Hybridization Chain Reaction Fluorescence In Situ Hybridization (HCR FISH) method to detect cryptic exons. Finally, single-cell RNA sequencing (scRNAseq) and mass spectrometry-based proteomics were conducted to capture the global cellular response to the mutation.

Results

Expanding the Clinical Spectrum

The study successfully linked ANXA11 mutations to clinically diagnosed corticobasal syndrome, a finding supported by queries of large neurodegenerative disease databases. This establishes CBS as a distinct phenotype within the ANXA11 clinical spectrum, which previously centered on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Neuronal Transport Breakdown and TDP-43 Pathology

In iPSC-derived neurons, the P93S mutation severely disrupted the protein's normal function. Live-cell imaging revealed a 75% decrease in the colocalization of ANXA11 with lysosomes, a critical step for RNA granule transport. This tethering failure led to a 15% reduction in axonal beta-actin RNA.

Furthermore, the mutation triggered hallmark features of TDP-43 proteinopathy. Mutant neurons exhibited a significant loss of nuclear TDP-43, with mean intensity dropping from 0.386 in controls to 0.185. This loss of nuclear function resulted in a 3.5-fold increase in STMN2 cryptic exons and a 37% increase in UNC13A cryptic transcripts—abnormal splicing products that are highly specific markers of TDP-43 dysfunction.

Microglial Immune Dysregulation

One of the most striking findings was the profound impact of the ANXA11 mutation on microglia. While ANXA11 is well-known for its role in neuronal axonal transport, multiomic analysis showed that the P93S variant caused more extensive transcriptomic and proteomic changes in microglia than in neurons. Proteomics identified 684 differentially expressed proteins in microglia compared to 434 in neurons. These changes were primarily associated with innate immune responses, lipid metabolism, and interferon signaling pathways, suggesting that neuroinflammation is a primary driver of the disease rather than a secondary response.

Discussion

This research highlights a critical limitation of current in silico prediction tools. The P93S mutation resides in a "low complexity domain" (LCD) of ANXA11. Because these regions are intrinsically disordered and often lack conservation across species, standard algorithms frequently misclassify pathogenic mutations in these domains as benign. The structural rigidity provided by prolines in these domains is essential; replacing a proline with a serine (P93S) disrupts the protein's ability to facilitate RNA transport.

The study also underscores the importance of considering non-neuronal cells in neurodegenerative disease. The significant immune signature observed in microglia suggests that ANXA11-related pathologies may share mechanisms with autoimmune conditions, such as sarcoidosis, where ANXA11 has also been implicated.

Conclusion

By integrating clinical data with iPSC-derived cellular models and multiomics, this study provides a robust framework for the biological validation of VUS. The findings definitively classify the ANXA11 P93S variant as pathogenic, expand the clinical range of ANXA11 mutations to include CBS, and implicate both neuronal transport failure and microglial dysfunction in the disease's pathophysiology. This approach offers a scalable model for improving variant annotation and diagnostic accuracy in the era of genomic medicine.

Summary updated

Abstract

As genetic testing has become more accessible and affordable, variants of uncertain significance (VUS) are increasingly identified, and determining whether these variants play causal roles in disease is a major challenge. The known disease-associated Annexin A11 (ANXA11) mutations result in ANXA11 aggregation, alterations in lysosomal-RNA granule co-trafficking, and TDP-43 mis-localization and present as amyotrophic lateral sclerosis or frontotemporal dementia. We identified a novel VUS in ANXA11 (P93S) in a kindred with corticobasal syndrome and unique radiographic features that segregated with disease. We then queried neurodegenerative disorder clinic databases to identify the phenotypic spread of ANXA11 mutations. Multi-modal computational analysis of this variant was performed and the effect of this VUS on ANXA11 function and TDP-43 biology was characterized in iPSC-derived neurons. Single-cell sequencing and proteomic analysis of iPSC-derived neurons and microglia were used to determine the multiomic signature of this VUS. Mutations in ANXA11 were found in association with clinically diagnosed corticobasal syndrome, thereby establishing corticobasal syndrome as part of ANXA11 clinical spectrum. In iPSC-derived neurons expressing mutant ANXA11, we found decreased colocalization of lysosomes and decreased neuritic RNA as well as decreased nuclear TDP-43 and increased formation of cryptic exons compared to controls. Multiomic assessment of the P93S variant in iPSC-derived neurons and microglia indicates that the pathogenic omic signature in neurons is modest compared to microglia. Additionally, omic studies reveal that immune dysregulation and interferon signaling pathways in microglia are central to disease. Collectively, these findings identify a new pathogenic variant in ANXA11, expand the range of clinical syndromes caused by ANXA11 mutations, and implicate both neuronal and microglia dysfunction in ANXA11 pathophysiology. This work illustrates the potential for iPSC-derived cellular models to revolutionize the variant annotation process and provides a generalizable approach to determining causality of novel variants across genes.
BibTeX
@inproceedings{snyder2023anxa,
  author = {Allison Snyder and Veronica H. Ryan and James Hawrot and Sydney Lawton and Daniel M. Ramos and Yue Qi and Kory Johnson and Xylena Reed and Nicholas L. Johnson and Aaron W. Kollasch and Megan F. Duffy and Lawren VandeVrede and J. Nicholas Cochran and Bruce L. Miller and Camilo Toro and Bibiana Bielekova and Jennifer S. Yokoyama and Debora S. Marks and Justin Kwan and Mark Cookson and Michael E. Ward},
  title = {{An ANXA11 P93S variant dysregulates TDP-43 and causes corticobasal syndrome}},
  booktitle = {Research Square},
  year = {2023},
  doi = {10.21203/rs.3.rs-3462973/v1},
}
Figure